Treatment of 61 Rapid Progressive Central Precocious Puberty Girls with Combined Therapy of Ziyin Xiehuo Formula (滋阴泻火方) and Megestrol: A Randomized Controlled Trial
|更新时间:2023-06-30
|
Treatment of 61 Rapid Progressive Central Precocious Puberty Girls with Combined Therapy of Ziyin Xiehuo Formula (滋阴泻火方) and Megestrol: A Randomized Controlled Trial
Journal of Traditional Chinese MedicineVol. 64, Issue 13, Pages: 1336-1342(2023)
HAN Xinghui,SUN Yanyan,WANG Yonghong,et al.Treatment of 61 Rapid Progressive Central Precocious Puberty Girls with Combined Therapy of Ziyin Xiehuo Formula (滋阴泻火方) and Megestrol: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(13):1336-1342.
HAN Xinghui,SUN Yanyan,WANG Yonghong,et al.Treatment of 61 Rapid Progressive Central Precocious Puberty Girls with Combined Therapy of Ziyin Xiehuo Formula (滋阴泻火方) and Megestrol: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(13):1336-1342.DOI: 10.13288/j.11-2166/r.2023.13.009.
Treatment of 61 Rapid Progressive Central Precocious Puberty Girls with Combined Therapy of Ziyin Xiehuo Formula (滋阴泻火方) and Megestrol: A Randomized Controlled Trial
To observe the therapeutic effect of combined therapy of
Ziyin Xiehuo Formula
(滋阴泻火方, ZXF) and megestrol in the treatment of girls with rapid progressive central precocious puberty.
Methods
2
A total of 130 girls with rapid progressive central precocious puberty were randomized into the treatment group (65 cases) and control group (65 cases). ZXF granules (30 g per time, twice daily) and megestrol tablets (6 or 8 mg per day with three times) were administered orally in the treatment group, while subcutaneous injection of hormone-releasing hormone analogue (GnRHa) and leuprolide acetate microspheres injection (the initial dose was 3.75 mg for 4 weeks, then the dose was determined based on the weight as to 80 μg/kg, once every 4 weeks) were given to the control group, both for 6 months. The mammary nucleus diameter and the proportion of children with nucleus that retract, traditional Chinese medicine (TCM) syndrome scores, size of uterus and ovary, follicle diameter, height and X-ray bone age, growth rate and body mass were observed before and after treatment in both groups. And the liver and kidney function and adverse reactions were assessed to evaluate the safety.
Results
2
Finally, 123 cases including 61 cases in the treatment group and 62 cases in the control group were included in the analysis. At 6-month treatment, there were 52 children (85.25%) with mammary nucleus that retract in the treatment group and 54 children (87.10%) in the control group, with no significant difference (
P
>0.05). The mammary nucleus diameter and follicle diameter reduced, the bone age, height, and body mass significantly increased in both groups after treatment (
P
<0.05 or
P
<0.01); TCM syndrome scores significantly decreased in the treatment group, and the sizes of uterus and ovary were reduced in the control group after treatment (
P
<0.01). Compared to those in the control group, TCM syndrome scores were lower, while the sizes of uterus and ovary were greater, follicle diameter and growth rate were higher in the treatment group (
P
<0.01). No serious adverse reactions occurred.
Conclusion
2
In the treatment of girls with rapid progressive central precocious puberty, ZXF combined with megestrol can inhibit the growth of mammary nucleus, delay the development of uterus and ovary, inhibit the advanced trend of bone age and will not cause significant height growth deceleration.
FAIENZA MF , BRUNETTI G , ACQUAFREDDA A , et al . Metabolic outcomes,bone health,and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues [J]. Horm Res Paediatr , 2017 , 87 ( 3 ): 162 - 169 .
CORRIPIO R , SORIANO-GUILLÉN L , HERRERO FJ , et al . Changes in body mass index in girls with idiopathic central precocious puberty under gonadotropin-releasing hormone analogue therapy: the Spanish registry [J]. Horm Res Paediatr , 2016 , 86 ( 3 ): 154 - 160 .
BANGALORE KRISHNA K , FUQUA JS , ROGOL AD , et al . Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium [J]. Horm Res Paediatr , 2019 , 91 ( 6 ): 357 - 372 .
SEMINARA S , STAGI S , CANDURA L , et al . Changes of thyroid function during long-term hGH therapy in GHD children. A possible relationship with catch-up growth? [J]. Horm Metab Res , 2005 , 37 ( 12 ): 751 - 756 .
CUTFIELD WS , WILTON P , BENNMARKER H , et al . Incidence of diabetes mellitus and impaired glucose tole-rance in children and adolescents receiving growth-hormone treatment [J]. Lancet , 2000 , 355 ( 9204 ): 610 - 613 .
SUN W , HAN XH , WANG YH , et al . Effectiveness of ZiYin Xiehuo granules and Zishen Qinggan granules on partial precocious puberty in girls:a multicenter,rando-mized,single-blind,controlled trial [J]. J Tradit Chin Med , 2018 , 38 ( 5 ): 740 - 745 .
COMITE F , CUTLER GJ , RIVIER J , et al . Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone.A preliminary report [J]. N Engl J Med , 1981 , 305 ( 26 ): 1546 - 1550 .
Efficacy and Economic Evaluation of Weishi Qingjin Formula (苇石清金方)in the Treatment of Adult Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome:A Multicenter Retrospective Real-World Cohort Study
Challenges and Recommendations for Implementing Key Technologies in Decentralized Clinical Trials of Traditional Chinese Medicine
The Philosophy and Practical Pathway of "Dao (道)-Shen (神)-Formula" in Traditional Chinese Medicine
WANG Qingguo's Experience in Treatment of Headache Based on the Concept of "Achieving Harmony by Unblocking and Balancing"
A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind